Your session is about to expire
← Back to Search
Other
High Flow Nasal Cannula vs Low Flow Oxygen for Respiratory Failure
N/A
Waitlist Available
Led By Ivan Pavlov, M.D.
Research Sponsored by Hôpital de Verdun
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Acute Hypercapnic respiratory failure with pH < 7.35 and pCO2 > 45 mmHg
Adult patients > 18 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 hour, 6 hours, 24 hours, and daily until cessation of oxygen therapy, up to a maximum of 7 days
Awards & highlights
Study Summary
This trial is looking at whether high flow nasal cannula (HFNC) can help people with respiratory problems who can't tolerate non-invasive ventilation (NIV).
Who is the study for?
This trial is for adults over 18 with non-severe hypercapnic respiratory failure, which means they have high levels of carbon dioxide in their blood and a lower than normal pH. It's not for those who can't read English or French, are pregnant, have certain severe conditions like shock or coma, drug-induced hypercapnia, or need immediate ventilation.Check my eligibility
What is being tested?
The study compares two ways to give oxygen: High flow nasal cannula (HFNC) versus conventional low flow methods in patients with COPD experiencing high CO2 levels. The goal is to see if HFNC can correct gas exchange issues without needing mechanical ventilation.See study design
What are the potential side effects?
Potential side effects may include discomfort from the nasal cannula or mask used for oxygen delivery. There could also be risks associated with receiving too much or too little oxygen such as dryness of the airways, nosebleeds, and breathlessness.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have severe breathing problems with high CO2 levels and low pH in my blood.
Select...
I am over 18 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 hour, 6 hours, 24 hours, and daily until cessation of oxygen therapy, up to a maximum of 7 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 hour, 6 hours, 24 hours, and daily until cessation of oxygen therapy, up to a maximum of 7 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proportion of patients progressing to NIV in each cohort
Secondary outcome measures
Admission to the intensive care unit
Heart rate
Hospital length of stay
+9 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: High Flow Nasal CannulaExperimental Treatment1 Intervention
Group II: Conventional Oxygenation with low flow cannulaActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
High flow nasal cannula
2019
N/A
~870
Find a Location
Who is running the clinical trial?
Hôpital de VerdunLead Sponsor
3 Previous Clinical Trials
337 Total Patients Enrolled
Ivan Pavlov, M.D.Principal InvestigatorCIUSSS-Centre-Sud-de-l'Île-de-Montréal
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have not had a respiratory or heart arrest.I have severe breathing problems with high CO2 levels and low pH in my blood.You have a Glasgow Coma Scale (GCS) score of 8 or lower.You are in shock if your blood pressure is very low, even after getting fluids.I have high carbon dioxide levels in my blood due to drug side effects or a non-lung related cause.I am over 18 years old.You need immediate help breathing using a machine or other medical devices.You cannot use non-invasive ventilation.I cannot read or understand French or English.My care plan does not include using a ventilator.Your body's acidity level is very low, below 7.15.I have high CO2 levels due to a severe asthma attack.You cannot use high-flow nasal cannula (HFNC) for medical reasons.
Research Study Groups:
This trial has the following groups:- Group 1: High Flow Nasal Cannula
- Group 2: Conventional Oxygenation with low flow cannula
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any openings left for participants in this experiment?
"According to the information on clinicaltrials.gov, this medical study is no longer in need of participants, having been initially published on October 1st 2022 and last updated on August 9th 2022. However, there are 192 other studies that currently require volunteers."
Answered by AI
Who else is applying?
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
Share this study with friends
Copy Link
Messenger